The estimated Net Worth of Marc Umscheid is at least $11.1 Tisíc dollars as of 10 August 2017. Marc Umscheid owns over 600 units of Sonoma Pharmaceuticals stock worth over $11,092 and over the last 8 years Marc sold SNOA stock worth over $0.
Marc has made over 2 trades of the Sonoma Pharmaceuticals stock since 2017, according to the Form 4 filled with the SEC. Most recently Marc bought 600 units of SNOA stock worth $3,186 on 10 August 2017.
The largest trade Marc's ever made was buying 750 units of Sonoma Pharmaceuticals stock on 6 March 2017 worth over $5,115. On average, Marc trades about 270 units every 31 days since 2017. As of 10 August 2017 Marc still owns at least 3,392 units of Sonoma Pharmaceuticals stock.
You can see the complete history of Marc Umscheid stock trades at the bottom of the page.
Marc's mailing address filed with the SEC is C/O SONOMA PHARMACEUTICALS, 1129 NORTH MCDOWELL BLVD., PETALUMA, CA, 94954.
Over the last 8 years, insiders at Sonoma Pharmaceuticals have traded over $0 worth of Sonoma Pharmaceuticals stock and bought 25,155 units worth $125,359 . The most active insiders traders include Frederick J Sandford, Sharon Barbari a Robert E Miller. On average, Sonoma Pharmaceuticals executives and independent directors trade stock every 27 days with the average trade being worth of $4,840. The most recent stock trade was executed by Robert E Miller on 12 March 2018, trading 2,400 units of SNOA stock currently worth $9,744.
sonoma pharmaceuticals, inc., develops and produces stabilized hypochlorous acid (hocl) products for various applications, including wound care, animal health care, eye care, oral care, and dermatological conditions in the united states and internationally. the company offers epicyn, an antimicrobial facial cleanser; levicyn, a hypochlorous acid (hocl) based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; celacyn gel, a product indicated to promote healing through the management of new and old scars resulting from surgical procedures and trauma wounds or burns; sebuderm, a product indicated to manage and relieve the burning, itching, pain, and distraction associated with seborrhea and seborrheic dermatitis; and ceramax, a lipogrid based skin barrier cream for management of dry itchy skin, minor skin irritations, rashes, and inflammation caused by various skin conditions, as well as loyon for the management of skin scal
Sonoma Pharmaceuticals executives and other stock owners filed with the SEC include: